NO DIFFERENCE IN IMMUNOGENICITY OF THE ORIGINAL AND BIOSIMILAR INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Karin Malíčková 1
Dana Duricova 2
Martin Kolar 2
Martin Bortlík 3
Veronica Hruba
Nadezda Machkova
Katarina Mitrova
Martin Lukas
Milan Lukas
1 Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Medical Faculty and General Teaching Hospital, Charles University, Prague, Czech Republic
2 ISCARE I.V.F. a.s., IBD Clinical and Research Center, Prague, Czech Republic
3 ISCARE I.V.F. a.s., IBD C
Conference
UEG Week 2016
Citation
United European Gastroenterology Journal; 2016: 2 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]